Abstract
Rheumatoid arthritis is associated with an increased risk of hematological malignancy as a result of the RA itself or its treatment. We report here on an unusual case of a 55-year-old female with long-standing rheumatoid arthritis and who was treated with low dose methotrexate and hydrochloroquine. She was diagnosed with chronic myelogenous leukemia that manifested with severe thrombocytosis and basophilia, and this was treated with imatinib mesylate. After 6 months, she achieved a complete cytogenetic response of the CML and a complete resolution of all the RA symptoms without DMARDs.
Introduction
Patients with Rheumatoid Arthritis (RA) face a double-edged sword: the chronic inflammation of the disease itself, combined with the long-term use of immunosuppressive drugs like methotrexate, significantly increases their risk of developing hematological malignancies such as leukemia and lymphoma. When a patient develops both an autoimmune disorder and cancer, clinical management becomes a complex balancing act. However, this challenge also presents a unique research opportunity. By observing how a patient responds to cancer treatment, researchers can gain insights into the shared signaling pathways between malignancy and autoimmunity. This paper explores whether Imatinib mesylate—a tyrosine kinase inhibitor (TKI) typically reserved for cancer—can effectively manage the inflammatory symptoms of RA.
Case Presentation and Methods
The patient is a 55-year-old female with a 30-year history of RA. At the time of her leukemia diagnosis, she was being treated with low-dose methotrexate and hydroxychloroquine.
The methodology followed standard clinical diagnostic and monitoring protocols:
- Diagnosis: Chronic Myelogenous Leukemia (CML) was confirmed via bone marrow aspiration and Fluorescence In Situ Hybridization (FISH) to detect the BCR/ABL1 gene rearrangement, also known as the Philadelphia chromosome.
- RA Monitoring: Disease severity was tracked using the Disease Activity Score (DAS28), which evaluates joint tenderness and swelling, alongside inflammatory markers such as Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP).
- Intervention: Upon diagnosis of CML, the patient was started on 400 mg/day of Imatinib mesylate. Crucially, her previous RA medications were discontinued to observe the TKI's isolated effect on her autoimmune symptoms.
Results
The patient showed a dramatic response in both her hematological and rheumatological conditions:
- Leukemia Response: Within 6 months, the patient achieved a complete cytogenetic response. Her platelet count, which was severely elevated at 4,867,000/μL due to the CML, returned to a healthy 209,000/μL within just three weeks of starting treatment.
- RA Response: The patient reported a complete resolution of joint pain and morning stiffness. Her DAS28 score dropped from 4.55 to 1.9, indicating clinical remission. Her inflammatory markers normalized (ESR dropped to 9 mm/hr), and she remained in RA remission for two years while on Imatinib monotherapy.
Discussion and Conclusion
The success of Imatinib in this case likely stems from its multi-targeted inhibition. While primarily used to target the BCR-ABL protein in leukemia, Imatinib also inhibits other tyrosine kinases, including KIT, PDGFR, CSF1R, and Lck. These kinases, particularly PDGFR and Lck, play critical roles in RA by promoting the growth of inflammatory synovial cells, stimulating bone-destroying osteoclasts, and activating T-cells. This suggests that the molecular drivers of her leukemia and her joint inflammation shared a common signaling pathway that Imatinib successfully inhibited.
While this single-patient case report is dramatic, it is limited by its sample size. Imatinib is a potent drug with a significant side-effect profile, and its use as a primary treatment for RA requires careful risk-benefit analysis. However, this case adds to a growing body of evidence supporting the development of selective tyrosine kinase inhibitors for autoimmune diseases. Future research should investigate whether lower, less toxic doses of TKIs could be effective for treatment-resistant RA.
Summary updated